News | December 13, 2016

Dimension Therapeutics Announces FDA Acceptance of Investigational New Drug Application for DTX301 to Treat OTC Deficiency On Track to Initiate Phase 1/2 Global, Multi-Center Clinical Trial by Year End 2016 Most Advanced of Five Inherited Metabolic Disease Programs...

News | December 6, 2016

Arvinas Collaborators Present Data on BET PROTAC Degraders at 2016 ASH Annual Meeting NEW HAVEN, Conn., December 6, 2016 – Arvinas LLC, a private biotechnology company creating a new class of drugs known as PROTACs which function via targeted protein degradation,...

News | December 1, 2016

Deciphera Pharmaceuticals Reports Encouraging Clinical Results with DCC-2618 in Genetically-defined Cancers with Drug Resistant Mutations Waltham, MA | December 1, 2016 Advanced Kinase Inhibitors with Improved Tumor Targeting Offer Potential for Durable Responses in...

News | November 29, 2016

Arvinas Presents Data on its BET PROTAC Degraders at 2016 EORTC-NCI-AACR Symposium NEW HAVEN, Conn., November 29, 2016 – Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, today announced that data were presented...

News | November 16, 2016

Truveris Ranked Number 131 Fastest Growing Company in North America on Deloitte’s 2016 Technology Fast 500™ Nov 16, 2016 Truveris ranked 131 on Deloitte’s Technology Fast 500™, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences...

News | November 7, 2016

Versartis Presents Safety, Efficacy and IGF-I Data for Somavaratan in Pediatric Growth Hormone Deficiency at the 2016 Congress of the GRS & IGF Society Increasing somavaratan dose to the 3.5mg/kg twice-monthly now used in Phase 3 safely improved IGF-I SDS and...
tempus fringilla diam Sed felis Phasellus efficitur. at